Clinical trial
A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)
NCT02821754 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)
- Lead sponsor
- National Cancer Institute (NCI)
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- July 5, 2016
- Completion date
- December 31, 2022
- Enrollment
- 54 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
bile duct cancer, biliary tract neoplasms, cholangiocarcinoma, hepatocellular carcinoma, liver cancer